626 related articles for article (PubMed ID: 16336351)
21. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
22. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
23. Characterization of a transplantable hormone-responsive human prostatic cancer xenograft TEN12 and its androgen-resistant sublines.
Harper ME; Goddard L; Smith C; Nicholson RI
Prostate; 2004 Jan; 58(1):13-22. PubMed ID: 14673948
[TBL] [Abstract][Full Text] [Related]
24. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
25. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer.
Osman I; Scher HI; Drobnjak M; Verbel D; Morris M; Agus D; Ross JS; Cordon-Cardo C
Clin Cancer Res; 2001 Sep; 7(9):2643-7. PubMed ID: 11555574
[TBL] [Abstract][Full Text] [Related]
26. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
27. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.
Agoulnik IU; Vaid A; Nakka M; Alvarado M; Bingman WE; Erdem H; Frolov A; Smith CL; Ayala GE; Ittmann MM; Weigel NL
Cancer Res; 2006 Nov; 66(21):10594-602. PubMed ID: 17079484
[TBL] [Abstract][Full Text] [Related]
28. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model.
Krueckl SL; Sikes RA; Edlund NM; Bell RH; Hurtado-Coll A; Fazli L; Gleave ME; Cox ME
Cancer Res; 2004 Dec; 64(23):8620-9. PubMed ID: 15574769
[TBL] [Abstract][Full Text] [Related]
29. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R).
Ling MT; Wang X; Lee DT; Tam PC; Tsao SW; Wong YC
Carcinogenesis; 2004 Apr; 25(4):517-25. PubMed ID: 14688027
[TBL] [Abstract][Full Text] [Related]
30. Zanthoxyli Fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways.
Yang Y; Ikezoe T; Takeuchi T; Adachi Y; Ohtsuki Y; Koeffler HP; Taguchi H
Oncol Rep; 2006 Jun; 15(6):1581-90. PubMed ID: 16685399
[TBL] [Abstract][Full Text] [Related]
31. Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission.
Schiffer IB; Gebhard S; Heimerdinger CK; Heling A; Hast J; Wollscheid U; Seliger B; Tanner B; Gilbert S; Beckers T; Baasner S; Brenner W; Spangenberg C; Prawitt D; Trost T; Schreiber WG; Zabel B; Thelen M; Lehr HA; Oesch F; Hengstler JG
Cancer Res; 2003 Nov; 63(21):7221-31. PubMed ID: 14612517
[TBL] [Abstract][Full Text] [Related]
32. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
Chiu FL; Lin JK
Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
[TBL] [Abstract][Full Text] [Related]
33. Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential.
Ricciardelli C; Jackson MW; Choong CS; Stahl J; Marshall VR; Horsfall DJ; Tilley WD
Prostate; 2008 Jun; 68(8):830-8. PubMed ID: 18324648
[TBL] [Abstract][Full Text] [Related]
34. Antiandrogen-like actions of an antioxidant on survivin, Bcl-2 and PSA in human prostate cancer cells.
Gunawardena K; Campbell LD; Meikle AW
Cancer Detect Prev; 2005; 29(4):389-95. PubMed ID: 16139439
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway.
Lee SO; Lou W; Johnson CS; Trump DL; Gao AC
Prostate; 2004 Aug; 60(3):178-86. PubMed ID: 15176047
[TBL] [Abstract][Full Text] [Related]
36. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR).
Nickerson T; Chang F; Lorimer D; Smeekens SP; Sawyers CL; Pollak M
Cancer Res; 2001 Aug; 61(16):6276-80. PubMed ID: 11507082
[TBL] [Abstract][Full Text] [Related]
37. Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells.
Kominsky SL; Hobeika AC; Lake FA; Torres BA; Johnson HM
Cancer Res; 2000 Jul; 60(14):3904-8. PubMed ID: 10919667
[TBL] [Abstract][Full Text] [Related]
38. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
39. The role of c-Jun and c-Fos expression in androgen-independent prostate cancer.
Edwards J; Krishna NS; Mukherjee R; Bartlett JM
J Pathol; 2004 Oct; 204(2):153-8. PubMed ID: 15378488
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of prostate cancer cell survival after inhibition of AR expression.
Cohen MB; Rokhlin OW
J Cell Biochem; 2009 Feb; 106(3):363-71. PubMed ID: 19115258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
